Milestone Pharmaceuticals (NASDAQ:MIST) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Milestone Pharmaceuticals (NASDAQ:MIST) announced its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04), Zacks reports.

Milestone Pharmaceuticals Stock Performance

Shares of MIST traded up $0.10 during mid-day trading on Thursday, hitting $2.03. 1,012,188 shares of the company’s stock were exchanged, compared to its average volume of 374,690. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The business’s 50 day moving average is $2.02 and its two-hundred day moving average is $1.79. The firm has a market capitalization of $107.99 million, a P/E ratio of -2.50 and a beta of 1.83.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Friday, February 28th.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.